United States v. Ruvalcaba

Decision Date15 February 2022
Docket NumberNo. 21-1064,21-1064
Citation26 F.4th 14
Parties UNITED STATES of America, Appellee, v. José RUVALCABA, Defendant, Appellant.
CourtU.S. Court of Appeals — First Circuit

Brandon Sample, with whom Brandon Sample PLC was on brief, for appellant.

Jennifer Zacks, Assistant United States Attorney, with whom Nathaniel R. Mendell, Acting United States Attorney, was on brief, for appellee.

Before Barron, Selya, and Gelpí, Circuit Judges.

SELYA, Circuit Judge.

Presently before us is an appeal brought by defendant-appellant José Ruvalcaba, who is serving a life sentence for having led a drug-trafficking conspiracy. The appeal raises questions of first impression in this circuit.

To frame those questions, we note that the defendant's life sentence, imposed in 2009, encompassed a mandatory minimum, see 21 U.S.C. § 841(b)(1)(A) (2006), triggered by two prior convictions for felony drug offenses. While the defendant was serving his sentence, Congress passed the First Step Act (FSA) in December of 2018. See Pub. L. No. 115-391, 132 Stat. 5194. As relevant here, the FSA reduced certain enhanced mandatory minimum penalties (including those pursuant to section 841(b)(1)(A) ) and modified the criteria for qualifying prior offenses. See id. § 401, 132 Stat. at 5220. At the same time, the FSA amended the compassionate-release statute, see 18 U.S.C. § 3582(c)(1)(A), to allow prisoners to file their own motions for compassionate release, see FSA § 603(b), 132 Stat. at 5239.

In the wake of these changes, the defendant moved for compassionate release under section 3582(c)(1)(A)(i), alleging that there were extraordinary and compelling reasons for his release. The government opposed the motion. The district court, in an unpublished order, refused the requested relief.

On appeal, the defendant broadly contends that the district court erred by concluding that it lacked the authority to reduce his sentence because the FSA's changes could not support an extraordinary and compelling reason for compassionate release. We have not yet spoken definitively on the extent of a district court's discretion in determining whether extraordinary and compelling reasons for compassionate release exist. Specifically, we have yet to resolve whether the Sentencing Commission's current policy statement ( USSG § 1B1.13 ) is applicable to and, thus, binding upon district courts in adjudicating prisoner-initiated motions for compassionate release. Nor have we yet resolved whether a district court — when confronted with such a motion — may consider certain of the FSA's changes that were not made retroactive to sentences previously imposed.

After careful consideration, we hold that a district court — when adjudicating a prisoner-initiated motion for compassionate release — is not bound by the Sentencing Commission's current policy statement. We further hold that such a court may consider the FSA's non-retroactive changes in sentencing law on an individualized basis, grounded in a defendant's particular circumstances, to determine whether an extraordinary and compelling reason exists for compassionate release. Accordingly, we vacate the order of the district court and remand for further proceedings consistent with this opinion.

I

Our journey starts with a rehearsal of the relevant facts and travel of the case, including a description of the pertinent aspects of the FSA and the law pertaining to compassionate release.

The defendant led a sprawling drug-distribution and money-laundering conspiracy in the early 2000s. After his apprehension, the defendant was tried and found guilty of involvement in two interlocking conspiracies: a conspiracy to distribute and to possess with intent to distribute over 500 grams of methamphetamine, see 21 U.S.C. § 846, and a conspiracy to launder money, see 18 U.S.C. § 1956(h). On April 28, 2009, the district court sentenced him to life imprisonment on the drug-trafficking charge and to a concurrent 240-month term of immurement on the money-laundering charge. The defendant appealed, and we summarily affirmed. See United States v. Ruvalcaba, No. 09-1650 (1st. Cir. Jan. 7, 2010) (unpublished judgment).

The lifetime term of imprisonment reflected the enhanced mandatory minimum penalty that Congress had prescribed for defendants with two prior "felony drug offense[s]" pursuant to section 841(b)(1)(A). See 21 U.S.C. § 841(b)(1)(A) (2006). At the time of sentencing, the defendant had two earlier California felony drug convictions: a 2001 conviction for importation, sale, and distribution of methamphetamine and a 2001 conviction for possession of methamphetamine.

We fast-forward to the spring of 2020, when the defendant moved for compassionate release under section 3582(c)(1)(A)(i), as amended by the FSA. Two of the FSA's provisions are critically important to the defendant's compassionate-release motion. First, during the more than thirty years before the FSA's passage, any motion for compassionate release had to be filed by the Director of the federal Bureau of Prisons (BOP). See 18 U.S.C. § 3582(c)(1)(A) (2012). The FSA amended the statute, allowing prisoners to file such motions on their own should the BOP decline to act.1 See FSA § 603(b), 132 Stat. at 5239.

Second, the FSA reconfigured the sentencing landscape through a series of revisions. Pertinently, it altered the scope of the statutory mandatory minimum penalties imposed pursuant to 21 U.S.C. § 841(b)(1)(A). See FSA § 401, 132 Stat. at 5220-21. This amendment reduced the mandatory minimum penalties in that section such that a defendant who had two or more prior qualifying convictions for drug offenses was no longer subject to a mandatory term of life imprisonment but, rather, to an incarcerative term of twenty-five years. See id. § 401(a)(2), 132 Stat. at 5220. For a defendant with only one qualifying prior conviction, the mandatory minimum term was reduced from twenty years to fifteen years. See id. And as part and parcel of this series of changes, the FSA modified the criteria for qualifying prior offenses by replacing the term "felony drug offense" with the newly-defined terms "serious drug felony" and "serious violent felony." Id. § 401(a)(1), 132 Stat. at 5220.

Congress did not make these changes — found in section 401 of the FSA — applicable to all persons previously convicted under section 841(b)(1)(A). Instead, Congress limited the retroactivity of those amendments. Id. § 401(c), 132 Stat. at 5221 ("[Section 401], and the amendments made by this section, shall apply to any offense that was committed before the date of enactment of this Act, if a sentence for the offense has not been imposed as of such date of enactment.").

Marshalling his case for compassionate release, the defendant emphasized that had he been sentenced after the enactment of the FSA, he would have had just one qualifying prior offense and would have been subject to a mandatory prison term of only fifteen years. His life sentence was so much more draconian that, in his view, the resultant sentencing disparity was "extraordinary and compelling." This was especially true, he added, because he was only forty-five years old and had been incarcerated on the drug-trafficking conspiracy charge for fourteen of those years.2

The defendant offered an alternative ground for compassionate release. His medical issues, he said, justified a sentence reduction. In a supplemental motion, he added that his medical conditions — along with the conditions of his confinement — rendered him uniquely susceptible to severe illness or death from COVID-19.

The district court denied the defendant's motions. As an initial matter, the court determined that the defendant had adequately exhausted his administrative remedies. See 18 U.S.C. § 3582(c)(1)(A). The court then turned to the question of whether an extraordinary and compelling reason existed sufficient to warrant compassionate release. Taking the first step along this road, the court explained that although the Sentencing Commission's current policy statement did not "directly address the FSA's" amendments to the compassionate-release statute, it "provide[d] helpful guidance." The court then rejected the defendant's "medical conditions" argument, reasoning that the BOP could adequately address the defendant's medical issues and that there was no persuasive evidence that the defendant was particularly susceptible to the ravages of COVID-19.

Shifting its focus to the FSA's reduction of the mandatory minimum penalties and the simultaneous modifications of the criteria for qualifying prior offenses, the district court disagreed that those changes could be an element of an extraordinary and compelling reason for compassionate release. In the court's estimation, the changes were prospective in effect and, therefore, any ensuing disparity could not be deemed extraordinary. To rule otherwise, the court suggested, would result in an inappropriate judicial exception to the prospective effect of the FSA's amendments and offend the principle that "[t]he court may not modify a term of imprisonment once it has been imposed." 18 U.S.C. § 3582(c).

This timely appeal followed. In it, the defendant challenges the district court's refusal to consider the FSA's nonretroactive changes in sentencing law as part of the "extraordinary and compelling" calculus. He does not challenge the district court's rejection of his plaint that his medical issues, standing alone, warranted compassionate release.

II

Section 3582(c)(1)(A) authorizes a court to reduce a term of imprisonment when "extraordinary and compelling reasons warrant such a reduction."3 A prisoner seeking such relief may file a motion after exhausting his administrative remedies. See 18 U.S.C. § 3582(c)(1)(A) ; United States v. Texeira-Nieves, 23 F.4th 48, 52-53 (1st Cir. 2022). To grant the motion, the district court must find both that the defendant has presented an "extraordinary and compelling" reason warranting a sentence reduction, 18 U.S.C. § 3582(c)(1)(A)(...

To continue reading

Request your trial
93 cases
  • United States v. McCall
    • United States
    • U.S. Court of Appeals — Sixth Circuit
    • December 22, 2022
    ...circumstances." McGee , 992 F.3d at 1048 ; see United States v. Chen , 48 F.4th 1092, 1098 (9th Cir. 2022) ; United States v. Ruvalcaba , 26 F.4th 14, 28 (1st Cir. 2022). Judge Moore advocates for this approach as well. (Moore Dissent pp. 29–30.) The Fourth Circuit's position goes a step fu......
  • United States v. Jenkins
    • United States
    • U.S. Court of Appeals — District of Columbia Circuit
    • October 11, 2022
    ... ... of its discretion. As nine other circuits have held, courts ... may consider these materials even in cases involving ... defendant-filed motions for compassionate release ... E.g. , United States v. Ruvalcaba , 26 F.4th ... 14, 23 (1st Cir. 2022); United States v. Andrews , 12 ... F.4th 255, 260 (3d Cir. 2021); United States v ... McCoy , 981 F.3d 271, 282 n.7 (4th Cir. 2020); United ... States v. Thompson , 984 F.3d 431, 433 (5th Cir. 2021); ... United States v. Tomes ... ...
  • United States v. Jenkins
    • United States
    • U.S. Court of Appeals — District of Columbia Circuit
    • October 11, 2022
    ...may consider these materials even in cases involving defendant-filed motions for compassionate release. E.g. , United States v. Ruvalcaba , 26 F.4th 14, 23 (1st Cir. 2022) ; United States v. Andrews , 12 F.4th 255, 260 (3d Cir. 2021) ; United States v. McCoy , 981 F.3d 271, 282 n.7 (4th Cir......
  • United States v. Chen
    • United States
    • U.S. Court of Appeals — Ninth Circuit
    • September 14, 2022
    ...when determining whether extraordinary and compelling reasons for compassionate release exist in a particular case. United States v. Ruvalcaba , 26 F.4th 14 (1st Cir. 2022) ; United States v. Maumau , 993 F.3d 821 (10th Cir. 2021) ; United States v. McCoy , 981 F.3d 271 (4th Cir. 2020). The......
  • Request a trial to view additional results
1 firm's commentaries

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT